Stand Up To Cancer

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer. Read More

John Wilson, Ph.D., assistant professor of Chemical and Biomolecular Engineering and of Biomedical Engineering at Vanderbilt University, has received an Innovative Research Grant from Stand Up To Cancer (SU2C). Wilson is among 10 early-career scientists to receive the grant awards focused on immuno-oncology. Read More

Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer. Read More

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines. Read More

A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies. Read More

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer. Read More

Jeffrey Sosman (Vanderbilt) Jeffrey Sosman, professor of medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance. Sosman is among the Dream Team’s principal investigators who… Read More